Tricuspid regurgitation (TR) is a highly prevalent valvular heart disease and it correlates with an increased risk of cardiovascular events and death at long-term follow-up. Functional tricuspid regurgitation accounts for over 90% of TR and it is mainly due to annular dilatation or right ventricle dilatation. Most often, it is observed in patients with left-side valvular heart disease (with or without previous surgical correction) and pulmonary artery hypertension. Isolated TR is less frequent although burdened by high operative surgical mortality. This, together with an incomplete understanding of the disease, brought to a significant undertreatment in spite of the growing evidence of the impact of severe TR on mortality. Moreover, the uncertainties about the correct timing for intervention and the predictors of successful intervention contributed to limit TR treatment. Transcatheter therapies aiming at repairing or at replacing tricuspid valve represent novel and less-invasive alternatives to surgery and showed early promising results. The purpose of this review is to provide a complete and updated overview of TR pathology with a specific focus on current percutaneous treatments options, future challenges and directions.
Challenges and Future Perspectives of Transcatheter Tricuspid Valve Interventions: Adopt Old Strategies or Adapt to New Opportunities? Russo G, Taramasso M, Pedicino D, Gennari M, Gavazzoni M, Pozzoli A, Muraru D, Badano LP, Metra M, Maisano F. Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2398